A real-world study found evolocumab cut fatal or nonfatal heart attack risk 20% vs ezetimibe in adults with ASCVD and prior statin use.
|Webcasts|April 10, 2023
A customized approach to mRNA manufacturing
Author(s)Curia
Webinar Date/Time: Wed, May 10, 2023 11:00 AM EDT
Participate in this webinar to gain insights into methods for furthering mRNA production programs and learn how to identify areas for development and streamline processes.
Register Free:
Event Overview:
Diversity in mRNA therapies has mitigated advancements in the processes for manufacturing. IVT and capping reactions are not universal and must be finely tuned to each molecule based on composition, structure, and size. Using literature and experimental design, adapting each method to fit the molecule is necessary for hastening the optimization of mRNA development. In this webinar, you will gain insights into:
- Subject examination
- Identifying vital methodologies
- Refining and focusing target components
- Proper in-process analytics
Key Learning Objectives
- Identifying the variable/critical components involved in the mRNA production process
- Understanding the reasoning behind revisiting procedures
- Learning what metrics to use to navigate the mRNA process development
Who Should Attend
- Students/Researchers interested in developing better methods of in vitro transcribed RNA manufacturing
Speaker
Scott Alderucci
Director of mRNA Process Development & GMP operations
Curia Global, Inc.
Scott Alderucci is the director of process development overseeing the Process Development and GMP divisions of mRNA at Curia. He holds a scientific master’s degree and has 25 years of experience working in the field of biologics focused on DNA, mRNA and antibody platforms. He has worked within such institutions as Millennium Pharmaceuticals, Cellular Genomics, the State of Massachusetts, and Shire Pharmaceuticals prior to joining Curia. His current role is focused on providing research and development through GMP level production of a wide range of mRNA products to meet various program goals.
Register Free: https://www.biopharminternational.com/bp_w/customized-approach
Related to this article
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Johnson & Johnson's amivantamab (Rybrevant Faspro) won accelerated FDA approval for pretreated recurrent head and neck cancer.
Oxford spinout Alethio Therapeutics closed a $90 million Series A to take ATX-011, a monoclonal antibody against the G6B receptor, into Phase 1/2a studies in essential thrombocythemia. It is also developing a G6B-targeted ADC for myelofibrosis.
T-Therapeutics closed an oversubscribed $133 million Series B backed by Eli Lilly, JJDC, and others. The funding will take its first T-cell receptor bispecifics in cancer and autoimmune disease into clinical trials.
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
FDA’s draft framework would let sponsors add patient-specific genome editing variants to an approved BLA using in vitro data. Here is what the guidance proposes, what evidence it asks for, and what remains unresolved.
Healthy-volunteer data show sustained TL1A suppression and a profile supporting infrequent subcutaneous dosing. Caldera also licensed a second bispecific, targeting IL-17 and TL1A, from Qyuns Therapeutics.
Trending on BioPharm International
1
FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer
2
Amgen Real-World Study Links Evolocumab to Lower Heart Attack Risk Than Ezetimibe
3
Caldera’s IL-23p19×TL1A Bispecific CLD-423 Shows 40-Day Half-Life in Phase 1a, Supporting Dosing Every 8 to 12 Weeks
4
FAQ: What FDA’s Individualized Gene Editing Draft Guidance Means for Developers
5